Causal Biological Network Model for Inflammasome Signaling Applied for Interpreting Transcriptomic Changes in Various Inflammatory States
Virtually any stressor that alters the cellular homeostatic state may result in an inflammatory response. As a critical component of innate immunity, inflammasomes play a prominent role in the inflammatory response. The information on inflammasome biology is rapidly growing, thus creating the need for structuring it into a model that can help visualize and enhance the understanding of underlying biological processes. Causal biological network (CBN) models provide predictive power for novel disease mechanisms and treatment outcomes. We assembled the available literature information on inflammasome activation into the CBN model and scored it with publicly available transcriptomic datasets that address viral infection of the lungs, osteo- and rheumatoid arthritis, psoriasis, and aging. The scoring inferred pathway activation leading to NLRP3 inflammasome activation in these diverse conditions, demonstrating that the CBN model provides a platform for interpreting transcriptomic data in the context of inflammasome activation.
The optimal functioning of a cell, a tissue, an organ, and, ultimately, an organism as a whole depends on homeostasis and damage mitigation. Any deviation of the homeostatic range leads to a stress response, and when the stress response is insufficient to restore homeostasis, an inflammatory response is engaged . In the recent decade, it has become increasingly clear that inflammasomes are critical components of inflammatory response. Inflammasomes are multimolecular complexes that can assemble upon exposure to pathogen-associated molecular patterns (PAMP), damage-associated molecular patterns (DAMP), and diverse environmental insults . Depending on the stress sensor molecule, inflammasomes can be of different types, such as NLRP1 (NLR family pyrin domain containing 1), NLRP2, NLRP3, NLRC4 (NLR family CARD domain containing 4 or IPAF), AIM2 (absent in melanoma 2), IFI16 (interferon-gamma inducible protein 16), and pyrin inflammasomes . Inflammasome activation has been linked to viral, bacterial, and fungal infections [4–6] and autoinflammatory and autoimmune diseases such as gout and rheumatoid arthritis [7–9], as well as to other diverse conditions such as Alzheimer’s disease, atherosclerosis, aging, or obesity [10–14].
Generally, the two-signal mediated inflammasome activation model is accepted and discussed in the literature. During the first signal—the priming signal—inflammasome component and interleukin gene expressions are increased downstream of the NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) complex . Consequently, the inflammasome is activated following diverse signals, which often culminate at second messengers such as reactive oxygen species (ROS), ATP, or potassium levels [16–18]. The canonical inflammasome complex assembly results in procaspase 1 cleavage into active caspase 1 (CASP1), which subsequently cleaves and thus activates the proinflammatory cytokines interleukin 1B (IL1B) and IL18 . Cytokines play a crucial role in the innate immune response against invading pathogens; however, the inflammatory response can flare out of control. For example, exacerbated immune response as a result of NLRP3 inflammasome activation in pulmonary tissue can lead to acute lung injury and acute respiratory distress syndrome [20–22], which are common clinical manifestations of coronavirus disease 2019 (COVID-19). Indeed, studies show the engagement of the inflammasome in COVID-19 leading to uncontrolled inflammatory response and pyroptosis, an inflammatory form of cell death [23–25].
The complex biological state induced during an inflammatory response cannot be explained by analyzing isolated molecules or endpoints. While the information on the changes in separate molecular species is valuable, a holistic view that integrates committed inflammatory pathways and the interconnections between pathway molecules can provide enhanced understanding of the impacted biology. Compilation of the involved pathways in a network representation is a step toward comprehensive understanding of a system response. Such a network approach is a valuable tool in network medicine, which takes into account how the regulated molecules interact with each other and how information flows along the multiple pathways that constitute a given biological process or pathology [26, 27]. Organizing the established biological data into a network view can help link apparent unrelated processes and pathways, facilitating characterization of known or novel disease mechanisms and prediction of drug effects and treatment outcomes.
Furthermore, vast amounts of data generated through omics technologies, for example, transcriptomics, can be harnessed in concert with network models to maximize information acquisition. From the RNA expression values in transcriptomic datasets, the activity levels of their regulating factors can be extrapolated and used to score the entities of network models . Such an approach creates a powerful explorative tool by combining literature-derived network models with billions of data points that are publicly available. This methodology conforms to the 21st century paradigm for medical research, which shifts the research from animal tests to assessments in cells and tissues in the context of systems biology with the use of in silico tools [29, 30].
To characterize the mechanisms responsible for disease or toxicant exposure, we have published a series of causal biological network (CBN) models that capture unstructured information from scientific literature into scorable graphical representations. The network models were built using Biological Expression Language (BEL) , which converts molecular interactions described in natural language to semantic triples with source, relationship, and target by using a controlled vocabulary. This allows us to compute the triples into a graphical representation in which the nodes represent biological entities and the edges represent the interactions between the nodes. BEL also captures information on the experimental approach, including species, tissue/cell type, and disease state. The models are hosted in the CBN database (http://causalbionet.com) [32, 33]. The newest additions in CBN are a suite of models that describe mucociliary clearance , a zebrafish cardiotoxicity network model for ecotoxicology , and a suite of models that represent signaling pathways that contribute to inflammatory bowel disease . The website offers tools for browsing and downloading each network model. Finally, the network models can be scored using transcriptomic data to obtain genome-wide coverage of mRNA changes in the context of a biological process. The scoring principle is described in Materials and Methods and in several publications [37–41].
2. Materials and Methods
2.1. Literature Curation
Relevant scientific literature containing mechanistic data on inflammasome activation was identified as the first step in network building. Research articles were prioritized over review articles, and results sections were prioritized over the introduction, discussion, and conclusion sections in order to capture direct experimental evidence. Wherever applicable, the most granular sequence of causal events was captured. Scientific text curation was performed with BEL, which displays biological findings in a computable form. BEL converts the relationships between biological entities into statements of cause, relationship, and effect triples using controlled vocabularies facilitating the subsequent computation of the models. Biological entities of the cause and target are scripted in a namespace format of “BEL function (namespace identifier:“entity definition”),” for example, “p(HGNC:NLRP3).” Custom namespaces (e.g., PMIBP for a biological process) were created if the biological entities were not available in existing namespaces. Table 1 summarizes the BEL terminologies for the namespaces used in this study.
The namespaces were connected with causal or associative relationships based on literature evidence. The publication reference and details of the experimental model (such as species, organ/tissue/cell types, or cell lines) were annotated additionally to provide context to the statements. Contradicting evidence was curated without preferential treatment, along with experimental model annotations. The BEL statements for the inflammasome network model were derived from experiments conducted in human, mouse, and rat model systems. To avoid duplicate namespaces for the same gene curated from studies in different species, we orthologized the network model to single species nomenclature.
2.2. Network Model Assembly and Scoring
In order to generate a network view, BEL statements were compiled into a network assembly model by using OpenBEL framework 3.0.0 (https://github.com/OpenBEL/openbel-framework). The Cytoscape web application was used to visualize and analyze network properties . The model backbone consists of nodes, which are the biological entities connected by relationship edges. In addition to the backbone layer, the network model has a downstream layer that harbors information about mRNAs regulated by some of the entities in the model backbone. The downstream layer is based on a back-reasoning approach, where the activity of a backbone node is deduced from its own downstream transcript abundance . This collective mRNA signature was obtained from publicly available transcriptomic datasets. The activity of the nodes in the model backbone is inferred on the basis of the concordance of transcriptomic changes in the data (chosen datasets for scoring and analysis) with the mRNA nodes underneath the backbone nodes. Such an approach allows one to infer the activity status of the corresponding backbone node (inferred node: iNode) from scoring datasets instead of assuming that the mRNA abundance of the backbone node in the dataset corresponds with its protein activity. The datasets GSE51386, GSE55235, GSE2737, E-MEXP-839, and GSE11258 from public data repositories were used for scoring the inflammasome network model. For model scoring, a threshold-free enrichment method specific for iNode was applied using the Strength Network Perturbation Amplitude scoring algorithm . To illustrate graphically how backbone nodes are inferred on the basis of gene expression differences in the scoring dataset, the inference values were imported to the Cytoscape application and assigned to the model nodes.
3. Results and Discussion
3.1. The Inflammasome Model
In this work, we have built a CBN model for inflammasome activation. We curated scientific literature related to inflammasome activation from 55 research articles and compiled a network model with 297 nodes and 455 edges, which can be used to score the pathology of infections, diseases, treatments, and other conditions. The network model is centered on NLRP3 inflammasome activation, as it is the most studied and best characterized inflammasome. As inputs, the model contains nodes that represent toxins and various pathogenic and sterile insults. Toll-like receptors (TLR), sirtuin 1 (SIRT1), Beclin 1 (BECN1), NFκB complex, aryl hydrocarbon receptor (AHR), Z-DNA binding protein 1 (ZBP1), and mitogen-activated protein kinase (MAPK) signaling are some of the upstream regulators of the NLRP3 inflammasome complex. Caspase 1 (CASP1) and the subsequent cleavage and activation of IL1B and IL18 are among the downstream targets of the NLRP3 inflammasome complex. The inflammasome network model is available for browsing and download in the CBN database (http://causalbionet.com/).
3.2. Network Model Scoring with Transcriptomic Data
3.2.1. Mouse Lung Response to Viral Infection
To demonstrate how the inflammasome CBN model can be used to gain mechanistic insights into inflammatory response in tissues, we scored the network model with gene expression data from several publicly available datasets hosted in the Gene Expression Omnibus (GEO) repository. The transcriptomic dataset GSE51386 contains data on mouse lung response to severe acute respiratory syndrome (SARS) MA15 virus infection at 104 PFU. The lungs from SARS MA15-and mock-infected C57BL6 mice were dissected at 4 and 7 days post infection (dpi). The mRNA abundances in affected and control lung cells were scored against our iNode collection, and the results of the scoring show whether a given iNode is inferred to be activated, inhibited, or not impacted.
The iNode scoring algorithm inferred upregulation of NLRP3 and CASP1 at both 4 and 7 dpi, with a greater effect at a later time point (Figure 1). These nodes, which are an integral part of the NLRP3 inflammasome complex, receive the activating input from multiple upstream factors. Particularly, members of the NFκB pathway, including TLR2, TLR4, MYD88 (myeloid differentiation primary response 88), and the NFκB complex, were inferred to be upregulated upon virus infection, consistent with the NLRP3 inflammasome priming event. TNF (tumor necrosis factor) and its receptor were also inferred to be upregulated, although TRAF2 (TNF receptor-associated factor 2), through which TNF connects to NFκB in our CBN, was inferred to be significantly downregulated at both 4 and 7 dpi, which hinted at other parallel pathways involved in the infection-elicited inflammation. Furthermore, the AMPK (AMP-activated protein kinase) complex, a known inhibitory factor of NFκB, was inferred to be downregulated. Similarly, SIRT1, which blocks NFκB-DNA binding through deacetylation  and also functions as an inflammasome inhibitor, was also inferred to be downregulated. Some other inhibitory factors in the NFκB cascade, such as NFKBIA and MIR155 upstream of MYD88, were inferred to be upregulated; however, it appeared that positive signals toward NFκB overcame these inhibitory effects. Two circadian proteins, CLOCK and ARNTL (aryl hydrocarbon receptor nuclear translocator like, also known as BMAL1)—which have opposing effects on NFκB—were both inferred to be downregulated. NFκB upstream activator IRAK1 (interleukin 1 receptor-associated kinase 1) was also inferred to be downregulated. This complex regulation of NFκB could be a fine-tuning mechanism of inflammation control. In this context, it is important to note that NFκB was shown to also have inhibitory effects on NLRP3 inflammasome activation by promoting clearance of damaged mitochondria . DAMPs released during mitochondrial damage, such as mitochondrial ROS and mitochondrial DNA, are recognized as triggers for NLRP3 activation .
Scoring with a SARS MA15 virus-treated dataset further showed that NLRP3 inflammasome-activating factors, such as FFAR2 (free fatty acid receptor 2), BTK (Bruton’s tyrosine kinase), IRF1 (interferon regulatory factor 1), and ZBP1, were all inferred to be upregulated, although the inflammasome inhibitory AHR was also inferred to be upregulated. Inconsistent with its inflammasome-activating role, the purinergic receptor P2RX7 was inferred to be significantly downregulated at both time points after viral infection. The downstream effector molecules of inflammasome activation, IL1B and IL18, were inferred as significantly affected after virus infection. While, as expected, IL1B was inferred to be upregulated at both time points after viral infection, IL18 activity was inferred to be downregulated. This can be explained by signals other than NLRP3 inflammasome affecting IL18 activity. BCL2 apoptosis regulator and RHOA (ras homolog family member A)—inhibitors of NLRP1 activity and the pyrin inflammasome, respectively—were inferred to be upregulated, suggesting inhibition of both NLRP1 and pyrin inflammasome activities. In addition, various other factors are involved in IL18 production, such as JAK/STAT (Janus kinase/signal transducer and activator of transcription) or type I interferon signaling , and the alterations in these pathways can be reflected in the negative score of IL18 in the mouse lung tissues.
Taken together, our results are consistent with the innate immune response mounted after viral infection. The scoring results that were not in agreement with the established roles of the factors can offer new insights into the regulatory mechanisms of inflammasome biology during viral infection. It would be important to score more viral infection datasets to be able to extract the regulatory traits of factors that were performed inconsistent with their conventional roles in inflammation, such as IRAK1, NFκB, AHR, and P2RX7. Such regulatory traits will provide valuable information for elucidating the specific contribution of these factors during infection-provoked inflammation.
3.2.2. Inflammasome Activation during Osteoarthritis and Rheumatoid Arthritis
Next, we chose GEO dataset GSE55235, where the transcriptomic data were derived from human synovial tissues from osteoarthritis (OA) and rheumatoid arthritis (RA) patients and healthy controls. RA is an autoimmune joint disease characterized by chronic synovitis that progresses to the destruction of cartilage and bone. The NLRP3 inflammasome contributes to RA pathogenesis and severity [48, 49]. OA is a joint disease where cartilage is damaged because of wearing away during aging . Although commonly regarded as a wear-and-tear disease, there is evidence for an inflammatory component in OA [51, 52]. Indeed, our scoring results suggest that inflammasome components such as NLRP3, PYCARD (PYD and CARD domain containing), and CASP1 are activated in both diseases (Figure 2). NLRC4, an IPAF inflammasome component and stress sensor, was inferred to be significantly downregulated in the synovial tissues of OA patients. Interestingly, several inflammasome-activating factors—such as BTK, the NFκB complex, and beta-catenin (CTNNB1)—as well as ROS, calcium cations, and ATP levels were inferred to be downregulated. Our network model has captured paths downstream of NFκB and CTNNB1 that also lead to inflammasome inhibition. Even though it is an inflammasome priming factor, NFκB restricts inflammasome activation through sequestosome 1 (SQSTM1, also known as p62), which promotes the clearance of damaged mitochondria . While some studies suggest CTNNB1 to be an upstream promoting factor for the inflammasome [53, 54], CTNNB1 can also lead to inflammasome inactivation through inhibition of XBP1 (X-box binding protein 1), which, in turn, is an NLRP3 activator . Interestingly, XBP1 was also inferred to be downregulated in both OA and RA samples. This downregulation of inflammasome-promoting factors suggests that other pathways are involved in inflammasome activation and such a counterbalance might be an effective measure for preventing excessive and uncontrolled inflammatory response. It is interesting to note that IL1B levels were also inferred to be downregulated in OA samples, and the IL18 score did not reach a significant value in any disease sample.
Consistent with the captured biology, all scored entities in the inflammasome-activating IFNAR1/IRF1/ZBP1 axis were inferred to be upregulated in both disease samples. Conversely, inhibitory factors of the NLRP3 inflammasome, such as the AMPK complex, SIRT1, and AHR, were inferred to be downregulated; the pyrin inflammasome inhibitor RHOA was also inferred to be downregulated.
While many upstream signaling molecules had similar inferred activities for both OA and RA, the TNFRSF (TNF receptor superfamily), TLR2, TLR4, TNF, STAT1, and BCL2 had opposite inferred scores, hinting at molecular mechanistic differences between the two diseases. All these entities were inferred to be upregulated in the synovial tissues of RA patients (the TNF, TLR4, and BCL2 scores did not reach statistically significant values for RA) and downregulated in OA patients’ synovial tissues (the TLR2 and STAT1 scores did not reach statistically significant values for OA). Consistent with this finding, anti-TNF treatment has been reported to show beneficial outcomes in RA patients when compared with OA patients [56, 57].
3.2.3. Inflammasome Network Model Scoring in Psoriasis
Psoriasis is a complex immune-mediated skin disease, which can also manifest as joint inflammation . Psoriatic patients have a higher risk of comorbidities such as cardiovascular disease, inflammatory bowel disease, and nonalcoholic fatty liver disease [59–61]. There is a close link between this multifaceted disease and inflammasome activation; for example, an unbiased sequencing approach revealed inflammasome signaling as the highest differentially expressed pathway in psoriasis patients, whereby inflammasome activation was correlated with disease severity .
We have scored the inflammasome CBN model with transcriptomic dataset GSE2737, derived from biopsy samples of affected and unaffected skin areas from psoriatic patients compared with skin samples from healthy control subjects. Evidently, the affected active disease skin areas had a higher number of significantly scored inflammasome-related nodes (Figure 3). Active CASP1 and IL1B were among the nodes enriched in the affected skin samples. NLRP3 activity, however, was not significantly inferred to be regulated in the active disease and was inferred to be downregulated in the unaffected skin areas. Nevertheless, a recent study in psoriatic patients found high expression levels of inflammasome sensors NLRP3, NLRP1, and AIM2 in peripheral blood cells as well as higher plasma levels of IL1B and IL18 . A number of positive regulators of the inflammasome pathway—such as TLR2, TLR4, MYD88, the NFκB complex, FFAR2, calcium cations, BTK, and the TNF/TNFRSF—were inferred to be significantly upregulated in psoriatic skin samples relative to healthy skin samples. TNF, also inferred to be upregulated, is a recognized hallmark of psoriasis , and anti-TNF therapy is an approved treatment for moderate-to-severe plaque psoriasis, where it helps normalize CASP1 activity and plasma IL1B and IL18 levels and reduce skin and joint lesions [63, 65, 66].
AMPK and SIRT1, both being factors that limit inflammasome activation, were inferred to be downregulated in psoriatic patient skin samples, concordant with downstream inflammasome activation. Next, the antiapoptotic protein BCL2 was inferred to be upregulated in affected skin biopsy samples. A study from Iizuka et al. suggests premature keratinocyte death in psoriasis , and our scoring result in this case could be a part of a compensatory mechanism. Inconsistent with their inflammasome-activating roles, IRAK1, RIPK1 (receptor-interacting serine/threonine kinase 1), and FOXO3 (forkhead box O3) were inferred to be downregulated. This could be explained as a countervailing attempt of the affected tissue to halt excessive inflammation. The inferred upregulation of the inflammasome-inhibiting AHR can be explained in a similar fashion.
Overall, the inflammasome network model scoring with transcriptomic data from the skin samples of psoriatic patients was largely consistent with the curated literature findings. This holistic view of the network of pathways helps identify the routes that are highly involved in inflammasome activation and distinguish the ones that are not involved or are antagonizing to inflammatory response, thus informing potential drug treatment efforts.
3.2.4. Inflammasome Network Model Scoring in Aging Mouse Liver
In recent years, the inflammasome has emerged as an important factor implicated in metabolic and age-related diseases . AMPK, a central molecule in energy metabolism that is also involved in processes of aging, and SIRT1, a key factor implicated in aging, are among the upstream modulators of NLRP3 inflammasome activation. Of note, the activities of both these proteins were inferred to be downregulated in our network model scoring with transcriptomic data from SARS MA15 virus-infected mouse lungs and synovial tissues of arthritis patients. A very recent study on chronic viral infections suggests a common signature of immune dysfunction in viral infections and aging-related inflammation .
With an aim to determine inflammasome CBN model perturbations during a lifespan, we analyzed the E-MEXP-839 dataset from the ArrayExpress database. This dataset compares the mouse liver transcriptomic profiles of adult 16-, 96- and 130-week-old wild-type (WT) C57Bl/6J mice with those of 8-week-old WT mice. Mice at the age of 16 weeks are generally not affected by senescence, whereas mice over 24 months of age are considered very old and show apparent histological lesions associated with aging . Accordingly, we identified only six iNodes that were significantly impacted at all three ages; moreover, all iNodes that were inferred to be significantly regulated at two time points out of the three showed significant scores for the latter, that is, 96- and 130-week time points, with the exception of the TNFRSF family iNode, which was inferred to be down- or upregulated in the liver of 16- and 130-week-old WT mice, respectively. In Figure 4, we show a subnetwork of the inflammasome activation CBN model, including iNodes, that reached a statistically significant score in the mouse liver in at least two life stages. Some nodes that were inferred to be regulated at only one time point—such as ARNTL, the NFκB complex, and ROS—were included because of their bridging position in pathways leading to inflammasome activity modulation. Analysis of the last two time points showed clear inferred upregulation of proinflammatory entities such as IFNAR1, IRF1, ZBP1, TLR2, TLR4, MYD88, TNF, and the MAPK p38 family, inflammasome constituents NLRP3 and CASP1, and the inflammasome product, active IL1B. However, some proinflammatory factors were inferred to be downregulated, such as the NFκB complex (significant score only in 130-week-old mice) and XBP1. Conversely, we observed inferred downregulation of anti-inflammatory, antiaging molecules, such as SIRT1 and SOD1 (superoxide dismutase 1). The inferred scores of AMPK did not reach statistical significance at any time point. Concomitant with the decrease in SOD1 activity, ROS levels increased with age, creating an aging-accelerating milieu due to accumulated damage . Furthermore, from our CBN scoring data, we could conclude that liver cell death rate increased with age, as the activity of the antiapoptotic protein BCL2 was inferred to be downregulated at later life stages of the mice. Additionally, the activity of ZBP1, which is involved in PANoptosis, was inferred to be increased in 96- and 130-week-old WT mice. PANoptosis refers to collective activation of pyroptosis, apoptosis, and necroptosis, which can result, for example, from ZBP1 pathogen sensing [72–74].
This perturbation of multiple inflammatory pathways in old animals supports the crucial role of inflammation in aging processes. Our network model scoring methodology can potentially offer new targets for intervention for healthy and slow aging approaches.
3.2.5. Inflammasome Response to Potassium Treatment
In all previous examples here, inflammasome components were inferred to be activated, as expected. We next asked if the network model would react to a stimulus that is supposed to block inflammasome activity. Many stimuli converge on potassium efflux, which is an essential mechanism of inflammasome activation [75, 76]. We chose a dataset of potassium treatment in murine hippocampal neurons (GSE11258), where inflammasome activity was expected to be blocked. Many studies confirm the presence and activity of the NLRP3 inflammasome in the hippocampus [77–79]. Indeed, treatment with 50 mM KCl for 1, 3, or 6 h causes a time-dependent decrease in the inferred activities of inflammasome components such as NLRP3 and PYCARD (significant scores at 3 and 6 h of potassium treatment) (Figure 5). The CASP1 score did not reach statistical significance. A snapshot of the inflammasome network model shown in Figure 5 includes several infectious agents and chemicals that trigger potassium efflux and consequently activate the inflammasome. Some of them also contribute to inflammasome activation independent of potassium concentration, for example, through NFκB-induced NLRP3 gene transcription during the inflammasome priming step. Presumably, higher intracellular potassium levels can block the inflammasome-triggering potential of these stressors. An example of this blockage is shown in a study by Suzuki and colleagues, where an increase in extracellular potassium concentration inhibited inflammasome-dependent IL1B production triggered by lipopolysaccharide and ATP treatment . Both ATP (significant scores at 1 and 3 h of potassium treatment) and Ca2+ (significant scores at 3 and 6 h of potassium treatment)—which are upstream negative regulators of potassium levels in our network model—were inferred to be upregulated, likely to counteract the burden of KCl salt exposure. Through the purinergic receptor ATP-gated channel P2RX7, ATP can act as a potassium efflux agent, enabling the influx of calcium and sodium cations to change the membrane potential, which, in turn, facilitates potassium efflux through KCNK6 (potassium two pore domain channel subfamily K member 6, also known as TWIK2) [80, 81].
We have presented here a CBN model that describes inflammasome activation on the basis of causal molecular relationships extracted from pertinent research articles. We also scored the inflammasome model with transcriptomic data derived from a viral infection of the lungs, osteo- and rheumatoid arthritis, psoriasis, and aging. In all these diverse conditions, the pathways leading to NLRP3 inflammasome activation were significantly impacted, implying inflammasome involvement. More interestingly, some upstream modulating paths were differently affected in individual datasets, providing insights on disease- or condition-specific inflammasome regulation. It is important to emphasize that the results presented in this report are from a small number of studies, and the network scoring needs to be repeated with several other datasets to support our findings. Regardless, the approach is very powerful for generating new hypotheses that, once experimentally verified, could lead to the discovery of new and more efficient therapeutics against conditions that engage inflammasomes, such as viral infections and inflammatory and metabolic diseases. We are continuing these efforts by expanding the suite with network models for other relevant components of innate and adaptive immune biology, including neutrophils, macrophages, dendritic cells, natural killer cells, and B cells.
Currently, of the 120 potentially inferable nodes (protein and protein family activities, complexes, and microRNAs as well as some chemicals) in the inflammasome CBN model, only 55 are iNodes; that is, only 55 nodes have the downstream transcript layer populated with data from public datasets. As a consequence, more than half of the inflammasome network model backbone nodes were left out of the model scoring and discussion in this study. Future work will complement the current results and might lead to new exciting conclusions, especially toward explaining the causal inconsistencies in the affected pathway scores. The results shown here are just a glimpse of what model scoring can offer, and the true value will be in the analysis of noninvasive human samples (e.g., blood) for evaluating the systemic component in different disease stages and toxic exposures and upon drug treatment or postvaccination responses.
The inflammasome network model is available in the CBN database (http://causalbionet.com/).
Conflicts of Interest
The authors declare that they have no conflicts of interest. All authors are employees of Philip Morris International.
This study was funded by Philip Morris International. The authors thank Florian Calvino, Sylvain Gubian, and Yang Xiang for computational support and Sindhoora Bhargavi Gopala Reddy for editorial assistance.
R. Chovatiya and R. Medzhitov, “Stress, inflammation, and defense of homeostasis,” Molecular Cell, vol. 54, no. 2, pp. 281–288, 2014.View at: Publisher Site | Google Scholar
D. Zheng, T. Liwinski, and E. Elinav, “Inflammasome activation and regulation: toward a better understanding of complex mechanisms,” Cell Discovery, vol. 6, no. 1, p. 36, 2020.View at: Publisher Site | Google Scholar
A. Malik and T.-D. Kanneganti, “Inflammasome activation and assembly at a glance,” Journal of Cell Science, vol. 130, no. 23, pp. 3955–3963, 2017.View at: Publisher Site | Google Scholar
B. Briard, T. Fontaine, P. Samir et al., “Galactosaminogalactan activates the inflammasome to provide host protection,” Nature, vol. 588, no. 7839, pp. 688–692, 2020.View at: Publisher Site | Google Scholar
C. Lupfer, A. Malik, and T.-D. Kanneganti, “Inflammasome control of viral infection,” Current Opinion in Virology, vol. 12, pp. 38–46, 2015.View at: Publisher Site | Google Scholar
Y. Zhong, Y. Lu, X. Yang et al., “The roles of NLRP3 inflammasome in bacterial infection,” Molecular Immunology, vol. 122, pp. 80–88, 2020.View at: Publisher Site | Google Scholar
Z. Li, J. Guo, and L. Bi, “Role of the NLRP3 inflammasome in autoimmune diseases,” Biomedicine & Pharmacotherapy, vol. 130, p. 110542, 2020.View at: Publisher Site | Google Scholar
P. J. Shaw, M. F. McDermott, and T.-D. Kanneganti, “Inflammasomes and autoimmunity,” Trends in Molecular Medicine, vol. 17, no. 2, pp. 57–64, 2011.View at: Publisher Site | Google Scholar
S. R. Kingsbury, P. G. Conaghan, and M. F. McDermott, “The role of the NLRP3 inflammasome in gout,” Journal of Inflammation Research, vol. 4, pp. 39–49, 2011.View at: Publisher Site | Google Scholar
I. Bertocchi, F. Foglietta, D. Collotta et al., “The hidden role of NLRP3 inflammasome in obesity‐related COVID‐19 exacerbations: lessons for drug repurposing,” British Journal of Pharmacology, vol. 177, no. 21, pp. 4921–4930, 2020.View at: Publisher Site | Google Scholar
F. Marin-Aguilar, “NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice,” Aging Cell, vol. 19, no. 1, Article ID e13050, 2020.View at: Google Scholar
H. Rodríguez-Hernández, “Obesity and inflammation: epidemiology, risk factors, and markers of inflammation,” International Journal of Endocrinology, vol. 2013, Article ID 678159, 11 pages, 2013.View at: Publisher Site | Google Scholar
M.-S. Tan, J.-T. Yu, T. Jiang, X.-C. Zhu, and L. Tan, “The NLRP3 inflammasome in Alzheimer’s disease,” Molecular Neurobiology, vol. 48, no. 3, pp. 875–882, 2013.View at: Publisher Site | Google Scholar
Y. Jin and J. Fu, “Novel insights into the NLRP 3 inflammasome in atherosclerosis,” Journal of American Heart Association, vol. 8, no. 12, Article ID e012219, 2019.View at: Publisher Site | Google Scholar
Y. He, H. Hara, and G. Núñez, “Mechanism and regulation of NLRP3 inflammasome activation,” Trends in Biochemical Sciences, vol. 41, no. 12, pp. 1012–1021, 2016.View at: Publisher Site | Google Scholar
J. F. Foley, “Potassium controls the inflammasome,” Science Signaling, vol. 6, no. 283, p. ec156, 2013.View at: Publisher Site | Google Scholar
A. Harijith, D. L. Ebenezer, and V. Natarajan, “Reactive oxygen species at the crossroads of inflammasome and inflammation,” Frontiers in Physiology, vol. 5, no. 352, p. 352, 2014.View at: Publisher Site | Google Scholar
A. Abderrazak, T. Syrovets, D. Couchie et al., “NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases,” Redox Biology, vol. 4, pp. 296–307, 2015.View at: Publisher Site | Google Scholar
K. Schroder and J. Tschopp, “The inflammasomes,” Cell, vol. 140, no. 6, pp. 821–832, 2010.View at: Publisher Site | Google Scholar
F. Cao, X. Tian, Z. Li et al., “Suppression of NLRP3 inflammasome by erythropoietin via the EPOR/JAK2/STAT3 pathway contributes to attenuation of acute lung injury in mice,” Frontiers in Pharmacology, vol. 11, no. 306, 2020.View at: Publisher Site | Google Scholar
J. J. Grailer, B. A. Canning, M. Kalbitz et al., “Critical role for the NLRP3 inflammasome during acute lung injury,” The Journal of Immunology, vol. 192, no. 12, pp. 5974–5983, 2014.View at: Publisher Site | Google Scholar
D. Li, W. Ren, Z. Jiang, and L. Zhu, “Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury,” Molecular Medicine Reports, vol. 18, no. 5, pp. 4399–4409, 2018.View at: Publisher Site | Google Scholar
A. C. Ferreira, V. C. Soares, I. G. de Azevedo-Quintanilha et al., “SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes,” Cell Death Discovery, vol. 7, no. 1, p. 43, 2021.View at: Publisher Site | Google Scholar
T. L. Freeman and T. H. Swartz, “Targeting the NLRP3 inflammasome in severe COVID-19,” Frontiers in Immunology, vol. 11, p. 1518, 2020.View at: Publisher Site | Google Scholar
M. Z. Ratajczak and M. Kucia, “SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells,” Leukemia, vol. 34, no. 7, pp. 1726–1729, 2020.View at: Publisher Site | Google Scholar
A.-L. Barabási and Z. N. Oltvai, “Network biology: understanding the cell’s functional organization,” Nature Reviews Genetics, vol. 5, no. 2, pp. 101–113, 2004.View at: Publisher Site | Google Scholar
H. Engin, A. Gursoy, R. Nussinov, and O. Keskin, “Network-based strategies can help mono- and poly-pharmacology drug discovery: a systems biology view,” Current Pharmaceutical Design, vol. 20, no. 8, pp. 1201–1207, 2014.View at: Publisher Site | Google Scholar
N. L. Catlett, A. J. Bargnesi, S. Ungerer et al., “Reverse causal reasoning: applying qualitative causal knowledge to the interpretation of high-throughput data,” BMC Bioinformatics, vol. 14, no. 1, p. 340, 2013.View at: Publisher Site | Google Scholar
G. Langley, C. P. Austin, A. K. Balapure et al., “Lessons from toxicology: developing a 21st-century paradigm for medical research,” Environmental Health Perspectives, vol. 123, no. 11, pp. A268–A272, 2015.View at: Publisher Site | Google Scholar
J. C. Madden, S. J. Enoch, A. Paini, and M. T. D. Cronin, “A review of in silico tools as alternatives to animal testing: principles, resources and applications,” Alternatives to Laboratory Animals, vol. 48, no. 4, pp. 146–172, 2020.View at: Publisher Site | Google Scholar
J. Fluck, S. Madan, S. Ansari et al., “Training and evaluation corpora for the extraction of causal relationships encoded in biological expression language (BEL),” Database, vol. 2016, 2016.View at: Publisher Site | Google Scholar
S. Boué, M. Talikka, J. W. Westra et al., “Causal biological network database: a comprehensive platform of causal biological network models focused on the pulmonary and vascular systems,” Database: The Journal of Biological Databases and Curation, vol. 2015, Article ID bav030, 2015.View at: Publisher Site | Google Scholar
M. Talikka, S. Boue, and W. K. Schlage, “Causal biological network database: a comprehensive platform of causal biological network models focused on the pulmonary and vascular systems,” in Computational Systems Toxicology, pp. 65–93, Springer, Heidelberg, Germany, 2015.View at: Publisher Site | Google Scholar
H. Yepiskoposyan, M. Talikka, S. Vavassori et al., “Construction of a suite of computable biological network models focused on mucociliary clearance in the respiratory tract,” Frontiers in Genetics, vol. 10, p. 87, 2019.View at: Publisher Site | Google Scholar
R. Li, A. Zupanic, M. Talikka et al., “Systems toxicology approach for testing chemical cardiotoxicity in larval zebrafish,” Chemical Research in Toxicology, vol. 33, no. 10, pp. 2550–2564, 2020.View at: Publisher Site | Google Scholar
A. Pedro, H. Y. Ruiz Castro, S. Gubian et al., “Systems biology approach highlights mechanistic differences between Crohn’s disease and ulcerative colitis,” Scientific Reports, vol. 11, no. 1, 2021.View at: Publisher Site | Google Scholar
F. Martin, “Systems toxicology approach to unravel early indicators of squamous cell carcinoma rate in rat nasal epithelium induced by formaldehyde exposure,” in International Conference on Practical Applications of Computational Biology & Bioinformatics, Springer, Heidelberg, Germany, 2019.View at: Publisher Site | Google Scholar
M. Talikka, V. Belcastro, S. Boué, D. Marescotti, J. Hoeng, and M. C. Peitsch, “Applying systems toxicology methods to drug safety,” Systems Medicine, Academic Press, Cambridge, MA, USA, 2021.View at: Publisher Site | Google Scholar
M. Talikka, “Systems toxicology meta-analysis–from aerosol exposure to nanotoxicology,” Current Opinion in Toxicology, vol. 16, pp. 39–48, 2019.View at: Publisher Site | Google Scholar
M. Talikka, N. Bukharov, W. S. Hayes et al., “Novel approaches to develop community-built biological network models for potential drug discovery,” Expert Opinion on Drug Discovery, vol. 12, no. 8, pp. 849–857, 2017.View at: Publisher Site | Google Scholar
F. Martin, A. Sewer, M. Talikka, Y. Xiang, J. Hoeng, and M. C. Peitsch, “Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models,” BMC Bioinformatics, vol. 15, no. 1, p. 238, 2014.View at: Publisher Site | Google Scholar
P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.View at: Publisher Site | Google Scholar
F. Martin, T. M. Thomson, A. Sewer et al., “Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks,” BMC Systems Biology, vol. 6, no. 1, p. 54, 2012.View at: Publisher Site | Google Scholar
H. Yang, W. Zhang, H. Pan et al., “SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity,” PLoS One, vol. 7, no. 9, Article ID e46364, 2012.View at: Publisher Site | Google Scholar
Z. Zhong, A. Umemura, E. Sanchez-Lopez et al., “NF-κB restricts inflammasome activation via elimination of damaged mitochondria,” Cell, vol. 164, no. 5, pp. 896–910, 2016.View at: Publisher Site | Google Scholar
M. Biasizzo and N. Kopitar-Jerala, “Interplay between NLRP3 inflammasome and autophagy,” Frontiers in Immunology, vol. 11, no. 2470, Article ID 591803, 2020.View at: Publisher Site | Google Scholar
E. Verweyen, D. Holzinger, T. Weinhage et al., “Synergistic signaling of TLR and ifnα/β facilitates escape of IL-18 expression from endotoxin tolerance,” American Journal of Respiratory and Critical Care Medicine, vol. 201, no. 5, pp. 526–539, 2020.View at: Publisher Site | Google Scholar
C. Guo, R. Fu, S. Wang et al., “NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis,” Clinical and Experimental Immunology, vol. 194, no. 2, pp. 231–243, 2018.View at: Publisher Site | Google Scholar
A. Kastbom, L. Ärlestig, and S. Rantapää-Dahlqvist, “Genetic variants of the NLRP3 inflammasome are associated with stroke in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 42, no. 10, pp. 1740–1745, 2015.View at: Publisher Site | Google Scholar
C. Ross, “A comparison of osteoarthritis and rheumatoid arthritis,” The Nurse Practitioner, vol. 22, no. 9, pp. 23–41, 1997.View at: Publisher Site | Google Scholar
M. J. McAllister, M. Chemaly, A. J. Eakin, D. S. Gibson, and V. E. McGilligan, “NLRP3 as a potentially novel biomarker for the management of osteoarthritis,” Osteoarthritis and Cartilage, vol. 26, no. 5, pp. 612–619, 2018.View at: Publisher Site | Google Scholar
Y. Zu, Y. Mu, Q. Li, S.-T. Zhang, and H.-J. Yan, “Icariin alleviates osteoarthritis by inhibiting NLRP3-mediated pyroptosis,” Journal of Orthopaedic Surgery and Research, vol. 14, no. 1, p. 307, 2019.View at: Publisher Site | Google Scholar
L. Fabris, R. Fiorotto, C. Spirli et al., “Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases,” Nature Reviews Gastroenterology & Hepatology, vol. 16, no. 8, pp. 497–511, 2019.View at: Publisher Site | Google Scholar
L. Huang, R. Luo, J. Li et al., “β-catenin promotes NLRP3 inflammasome activation via increasing the association between NLRP3 and ASC,” Molecular Immunology, vol. 121, pp. 186–194, 2020.View at: Publisher Site | Google Scholar
S. Yue, J. Zhu, M. Zhang et al., “The myeloid heat shock transcription factor 1/β-catenin axis regulates NLR family, pyrin domain-containing 3 inflammasome activation in mouse liver ischemia/reperfusion injury,” Hepatology, vol. 64, no. 5, pp. 1683–1698, 2016.View at: Publisher Site | Google Scholar
F. Brennan, “Inhibitory effect of tnf alpha; antibodies on synovial cell interleukin-1 production in rheumatoid arthritis,” The Lancet, vol. 334, no. 8657, pp. 244–247, 1989.View at: Publisher Site | Google Scholar
I. A. M. van den Oever, M. Baniaamam, S. Simsek et al., “The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis,” Rheumatology International, vol. 41, no. 2, pp. 319–328, 2021.View at: Publisher Site | Google Scholar
W.-H. Boehncke and M. P. Schön, “Psoriasis,” The Lancet, vol. 386, no. 9997, pp. 983–994, 2015.View at: Publisher Site | Google Scholar
A. A. Manolis, T. A. Manolis, H. Melita, and A. S. Manolis, “Psoriasis and cardiovascular disease: the elusive link,” International Reviews of Immunology, vol. 38, no. 1, pp. 33–54, 2019.View at: Publisher Site | Google Scholar
N. J. Korman, “Management of psoriasis as a systemic disease: what is the evidence?” British Journal of Dermatology, vol. 182, no. 4, pp. 840–848, 2020.View at: Publisher Site | Google Scholar
P. Nehring and A. Przybyłkowski, “Is psoriasis treatment a risk factor for inflammatory bowel disease?” Pharmaceutical Medicine, vol. 34, no. 4, pp. 257–262, 2020.View at: Publisher Site | Google Scholar
M. S. Garshick, T. J. Barrett, T. Wechter et al., “Inflammasome signaling and impaired vascular health in psoriasis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 39, no. 4, pp. 787–798, 2019.View at: Publisher Site | Google Scholar
D. Verma, S. Z. Fekri, G. Sigurdardottir, C. Bivik Eding, C. Sandin, and C. Enerbäck, “Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation,” Journal of Investigative Dermatology, vol. 141, no. 3, pp. 586–595, 2021.View at: Publisher Site | Google Scholar
N. Kanda, T. Hoashi, and H. Saeki, “Nutrition and psoriasis,” International Journal of Molecular Sciences, vol. 21, no. 15, 2020.View at: Publisher Site | Google Scholar
M. Chima and M. Lebwohl, “TNF inhibitors for psoriasis,” Seminars in Cutaneous Medicine and Surgery, vol. 37, no. 3, pp. 134–142, 2018.View at: Publisher Site | Google Scholar
K. Furue, T. Ito, and M. Furue, “Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis,” Cytokine, vol. 111, pp. 182–188, 2018.View at: Publisher Site | Google Scholar
H. Iizuka, H. Takahashi, M. Honma, and A. Ishida-Yamamoto, “Unique keratinization process in psoriasis: late differentiation markers are abolished because of the premature cell death,” The Journal of Dermatology, vol. 31, no. 4, pp. 271–276, 2004.View at: Publisher Site | Google Scholar
M. D. Cordero, M. R. Williams, and B. Ryffel, “AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging,” Trends in Endocrinology and Metabolism, vol. 29, no. 1, pp. 8–17, 2018.View at: Publisher Site | Google Scholar
C. J. Lopez Angel, E. A. Pham, H. Du et al., “Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination,” Proceedings of the National Academy of Sciences, vol. 118, no. 14, 2021.View at: Publisher Site | Google Scholar
C. F. Brayton, P. M. Treuting, and J. M. Ward, “Pathobiology of aging mice and GEM,” Veterinary Pathology, vol. 49, no. 1, pp. 85–105, 2012.View at: Publisher Site | Google Scholar
S. I. Liochev, “Reactive oxygen species and the free radical theory of aging,” Free Radical Biology and Medicine, vol. 60, pp. 1–4, 2013.View at: Publisher Site | Google Scholar
B. Banoth, S. Tuladhar, R. Karki et al., “ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis),” Journal of Biological Chemistry, vol. 295, no. 52, pp. 18276–18283, 2020.View at: Publisher Site | Google Scholar
T. Kuriakose and T.-D. Kanneganti, “ZBP1: innate sensor regulating cell death and inflammation,” Trends in Immunology, vol. 39, no. 2, pp. 123–134, 2018.View at: Publisher Site | Google Scholar
M. Zheng and T. D. Kanneganti, “The regulation of the ZBP1‐NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis),” Immunological Reviews, vol. 297, no. 1, pp. 26–38, 2020.View at: Publisher Site | Google Scholar
A. Di, S. Xiong, Z. Ye et al., “The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation,” Immunity, vol. 49, no. 1, pp. 56–65, 2018.View at: Publisher Site | Google Scholar
V. Pétrilli, S. Papin, C. Dostert, A. Mayor, F. Martinon, and J. Tschopp, “Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration,” Cell Death and Differentiation, vol. 14, no. 9, pp. 1583–1589, 2007.View at: Publisher Site | Google Scholar
Q. Li, S. Liu, X. Zhu et al., “Hippocampal PKR/NLRP1 inflammasome pathway is required for the depression-like behaviors in rats with neuropathic pain,” Neuroscience, vol. 412, pp. 16–28, 2019.View at: Publisher Site | Google Scholar
L. Niu, S. S. Luo, Y. Xu et al., “The critical role of the hippocampal NLRP3 inflammasome in social isolation-induced cognitive impairment in male mice,” Neurobiology of Learning and Memory, vol. 175, Article ID 107301, 2020.View at: Publisher Site | Google Scholar
D. Wang, J. Zhang, W. Jiang et al., “The role of NLRP3-CASP1 in inflammasome-mediated neuroinflammation and autophagy dysfunction in manganese-induced, hippocampal-dependent impairment of learning and memory ability,” Autophagy, vol. 13, no. 5, pp. 914–927, 2017.View at: Publisher Site | Google Scholar
T. Suzuki, K. Kohyama, K. Moriyama et al., “Extracellular ADP augments microglial inflammasome and NF-κB activation via the P2Y12 receptor,” European Journal of Immunology, vol. 50, no. 2, pp. 205–219, 2020.View at: Publisher Site | Google Scholar
B. Baeza-Raja, A. Goodyear, X. Liu et al., “Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis,” PLoS One, vol. 15, no. 6, Article ID e0234038, 2020.View at: Publisher Site | Google Scholar